Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing

21 May 2012 07:00

RNS Number : 7108D
ViaLogy PLC
21 May 2012
 



 

ViaLogy PLC ("ViaLogy" or "the Company")

 

Placing of £2.04 million

 

 

London, May 21, 2012. ViaLogy PLC (AIM: VIY), a provider of reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas Exploration and Production (E&P) companies based on proprietary, patented active signal processing technology, is pleased to announce that following a number of new contract wins, it has today conditionally raised a total of £2,045,000 (before expenses) through the placing of 74,363,637 ordinary shares ("the Placing Shares") at a price of 2.75p each ("the Placing") with existing and new institutional investors.

 

The Placing is completing in two tranches, the first being the issue of 38,000,000 Placing Shares at a price of 2.75p each to raise £1,045,000 (before expenses). Application has been made for the admission to trading on AIM of 38,000,000 new ordinary shares, which is expected to take place on 23 May 2012.

 

Following institutional demand, the second tranche is a placing of 36,363,637 Placing Shares at a price of 2.75p each to raise £1,000,000 (before expenses), conditional upon shareholder approval at a general meeting of the Company. A general meeting is expected to be held on or around 15 June 2012. A further announcement will be made in due course.

 

The net proceeds of the Placing will be used to strengthen the balance sheet and provide additional working capital to support ViaLogy's strategy.

 

CEO, Robert W. Dean, commented "2012 is shaping up to be a pivotal year for ViaLogy as we seek to fulfil our goal of widespread E&P industry adoption of our technology, QuantumRD. Since the start of the year we have successfully signed new contracts with three of the largest global E&P firms where QuantumRD will be used in some of the world's most important development fields; aiming to improve significantly on industry-standard techniques now in use. The net funds raised from this placing will provide additional resources as we seek to secure further contracts."

 

"In light of the current difficult market conditions for raising money, I was personally delighted that, following a short round of institutional meetings, we were able to increase the level of the placing due to institutional demand."

 

For the purposes of the Disclosure and Transparency Rules, on admission of the first tranche of the Placing Shares, the Company's total issued share capital consists of 890,243,274 ordinary shares of 1 penny each.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

 

Options Grant

 

Under the terms of his employment contract entered into on June 22 2010, Dr. Sandeep Gulati, ViaLogy's founder and Chief Technology Officer, is entitled to additional options awards in order to retain his interest in the ordinary share capital of ViaLogy. The Company will therefore issue 7,546,048 options exercisable at 1p per share.

 

 

 

 

 

For further information:

 

ViaLogy PLC

Terry Bond, Chairman - UK & Europe

+44 (0) 1235 834 734

Seymour Pierce (Nominated Advisor and Broker)

+44 (0) 207 107 8000

Mark Percy / Catherine Leftley (Corporate Finance )

Katie Ratner (Corporate Broking)

 

 

About ViaLogy:

ViaLogy provides reservoir characterization, geophysical imaging and hydrocarbon sizing services to global oil and gas customers based on proprietary, patented active signal processing technology. ViaLogy's QuantumRD platform assists clients in de-risking prospects over a broad range of subsurface lithologies and complex stratigraphies to generate drilling targets, position offsets and enhance recovery.

 

ViaLogy's core technology rapidly and accurately detects weak signals buried in high noise background and clutter, and is applicable to active/passive seismic, electromagnetic and magneto telluric data. By exploiting normally disregarded noise variations induced by changes in porosity, fluid presence and permeability across the formation, and adding computer-designed noise to the data, ViaLogy is able to amplify subtle noise variations to enhance areal and depth resolution in complex lithologies that are not achievable through conventional means. For more information on ViaLogy, visit www.vialogy.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEPGUUUAUPPGCU
Date   Source Headline
11th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
11th Jul 20239:33 amRNSForm 8.5 (EPT/RI) - Yourgene Health PLC
10th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
10th Jul 202311:44 amRNSForm 8.3 - Yourgene Health plc
10th Jul 202311:10 amRNSForm 8.3 - Yourgene
10th Jul 202310:10 amRNSForm 8.5 (EPT/RI)
10th Jul 20238:21 amRNSForm 8.3 - Yourgene Health PLC
7th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
7th Jul 202311:40 amRNSForm 8.5 (EPT/RI)
6th Jul 20232:00 pmRNSForm 8.3 - Yourgene Health plc
6th Jul 20231:00 pmRNSForm 8.5 (EPT/RI) - Replacement
6th Jul 202312:01 pmRNSForm 8.5 (EPT/RI)
6th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
6th Jul 20237:00 amRNSForm 8.3 - Yourgene Health PLC
5th Jul 20234:04 pmRNSForm 8.3 - Yourgene Health plc
5th Jul 20233:46 pmRNSFORM 8.3 - Yourgene Health Plc
5th Jul 20232:03 pmRNSForm 8.3 - Yourgene Health plc
5th Jul 20231:27 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc Amended
5th Jul 202312:30 pmRNSForm 8.3 - Yourgene Health Plc
5th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
5th Jul 202311:22 amRNSForm 8.3 - Yourgene Health plc
5th Jul 202311:03 amRNSForm 8.3 - YOURGENE HEALTH PLC
5th Jul 202310:33 amRNSForm 8.3 - Yourgene Health PLC
5th Jul 202310:23 amRNSForm 8.5 (EPT/RI)
4th Jul 20236:28 pmRNSForm 8.3 - Yourgene Health PLC
4th Jul 20235:41 pmRNSForm 8.3 -Yourgene Health plc
4th Jul 20234:53 pmRNSForm 8.3 - YourGene Health Plc
4th Jul 20233:57 pmRNSForm 8.3 - Yourgene Health plc
4th Jul 20232:26 pmRNSForm 8.3 - Yourgene Health plc
4th Jul 20231:56 pmRNSForm 8.3 - Yourgene Health plc
4th Jul 20231:56 pmRNSHolding(s) in Company
4th Jul 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
4th Jul 202311:57 amRNSForm 8.5 (EPT/RI)
4th Jul 20238:50 amRNSForm 8.3 - Yourgene Health PLC
3rd Jul 20234:04 pmRNSForm 8.3 - Yourgene Health PLC
3rd Jul 20237:00 amRNSRule 2.7 Announcement
13th Jun 20238:30 amRNSConditional disposal of Taiwan laboratory
6th Jun 202310:21 amRNSHolding(s) in Company
22nd May 20237:01 amRNSYGS to support MHC’s Boots agreement
22nd May 20237:00 amRNSDirectorate Change
5th May 202310:14 amRNSHolding(s) in Company
2nd May 20231:11 pmRNSHolding(s) in Company
27th Apr 20237:00 amRNSFull year unaudited trading update
18th Apr 20234:07 pmRNSHolding(s) in Company
31st Mar 20234:08 pmRNSHolding(s) in Company
24th Mar 20234:57 pmRNSHolding(s) in Company
17th Mar 20237:00 amRNSDirectorate Change
13th Mar 20237:00 amRNSStatement re. Silicon Valley Bank
21st Feb 202312:00 pmRNSChange of Website
27th Jan 20237:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.